Key result
Rivaroxaban combined with aspirin increased the primary patency rate at 6 months postoperatively to 92.96% compared to 82.86% with clopidogrel and aspirin in patients with lower limb arterial atherosclerosis occlusion after stent placement.
Why the study?
The study evaluated the short-term effects of rivaroxaban combined with aspirin in treating lower limb arterial atherosclerosis occlusion after stent placement.
Does rivaroxaban combined with aspirin improve vascular patency compared to clopidogrel combined with aspirin in patients with lower limb arterial atherosclerosis occlusion after stent placement?
Observational (n=141)
No
Does rivaroxaban combined with aspirin improve vascular patency compared to clopidogrel combined with aspirin in patients with lower limb arterial atherosclerosis occlusion after stent placement?
Absolute Event Rate: 92.96% vs 82.86%
p-value: p=0.022
Rivaroxaban combined with aspirin improves short-term vascular patency and anticoagulation profiles compared to clopidogrel and aspirin after lower limb stenting, without increasing bleeding risk.
May support rivaroxaban-based regimens after lower limb stenting; hypothesis-generating and leaves open need for RCTs.
This study evaluates the short-term effects of rivaroxaban combined with aspirin in treating lower limb arterial atherosclerosis occlusion after stent placement. Between July 2018 and December 2022, 141 patients with lower limb arterial atherosclerosis occlusion underwent stent placement and were divided into 2 groups based on the different treatments documented in the cases. The clopidogrel group (n = 70) received clopidogrel sulfate plus aspirin, while the rivaroxaban group (n = 71) received rivaroxaban plus aspirin. Outcomes included 1-year patency rate, bleeding events, acute embolism, amputation rates, coagulation indicators, and thromboelastography (TEG) parameters. The 1-year patency rate at 6 months postoperatively was higher in the rivaroxaban group (92.96%) compared to the clopidogrel group (P < .05). Both groups showed increased activated partial thromboplastin time (APTT) and prothrombin time (PT) and decreased D-dimer (D-D) and fibrinogen (FIB) levels after 6 months (P < .05). APTT and PT were higher, while D-D and FIB were lower in the rivaroxaban group (P < .05). TEG parameters showed increased reaction time (R), clot formation time (K), and clot index (CI) and decreased alpha angle (α), maximum amplitude (MA), and thromboelastometry (G) in both groups at 6 months. R, K, and CI were higher, and α, MA, and G were lower in the rivaroxaban group (P < .05). Bleeding events were similar between groups (P > .05), with 1 embolism case in the rivaroxaban group vs 2 in the clopidogrel group. Rivaroxaban combined with aspirin post-stent placement improved vascular patency and anticoagulation outcomes without increasing bleeding risk, offering an effective treatment option for lower limb arterial atherosclerosis occlusion.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) conducted an observational in Lower limb arterial atherosclerosis occlusion (n=141). Rivaroxaban combined with aspirin vs. Clopidogrel 75 mg/d + Aspirin 100 mg/d was evaluated on Primary patency rate at 6 months postoperatively (p=0.022). Rivaroxaban combined with aspirin increased the primary patency rate at 6 months postoperatively to 92.96% compared to 82.86% with clopidogrel and aspirin in patients with lower limb arterial atherosclerosis occlusion after stent placement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: